Endocrine Society Encourages Clinicians to Avoid Prescribing Compounded Hormones
April 01, 2016
|Contact: Aaron Lohr
Chief Communications Officer
|Contact: Jenni Glenn Gingery
Associate Director, Communications and Media Relations
Scientific Statement finds compounded products linked to potential risks, side effects
Boston, MA - A new Scientific Statement issued today by the Endocrine Society advises clinicians to avoid using compounded hormone medications to treat menopausal symptoms, female sexual dysfunction and other hormone conditions.
Sometimes called bioidentical compounded hormones, these products are typically a mixture of hormones. Compounded hormone medications are prepared by licensed professionals or facilities specifically for an individual’s use. Compounded medications are meant to be an alternative when an individual does not have access to or has an adverse reaction to a medication approved by the U.S. Food & Drug Administration.
Compounded hormone medications can be unsafe when inappropriate practices are used. More than 60 people died from cases of fungal meningitis attributed to compounded medications in a 2010 case.
“In extreme cases, advertisers have marketed compounded products as being able to prevent the ravages of aging and implied they are risk free,” said Nanette Santoro, MD, and the chair of the Society task force that developed the statement. “Few, if any, of these claims are supported by science. In fact, research has found many compounded hormones are associated with risks and side effects.”
Widely available hormone treatments approved by the U.S. Food & Drug Administration (FDA) offer effective and safe options for people with hormone disorders, and those approved treatments should be prescribed whenever possible, Santoro said.
Despite limited oversight of quality and dosage, bioidentical compounded hormones are used by millions of women to treat menopausal symptoms such as hot flashes and night sweats. Several market surveys indicate that custom-compounded menopausal hormone therapies earn $1 billion dollars in annual sales – enough to treat 2 million to 3 million women. The sales are equivalent to a quarter to a third of sales of menopausal hormone therapies approved by the U.S. Food & Drug Administration.
Although a large 2002 government study called the Women’s Health Initiative (WHI) raised concerns about menopausal hormone therapy raising the risks of blood clots, stroke, breast cancer and heart attacks in postmenopausal women, additional research conducted in the ensuing years has found that the level of risk depends on the individual woman’s health history, age and other factors. Experts have formed a consensus that the benefits of menopausal hormone therapy exceed the risks for most healthy women seeking relief of menopausal symptoms.
Some women turned to custom-compounded menopausal hormone therapy (MHT) because of a misconception that is was safer than FDA-approved treatments. No large-scale, long-term studies have been conducted to examine the effectiveness and safety of custom-compounded MHT. When women use a customized preparation of estrogen and/or progestin, there are concerns that it could be harmful due to an overdose of the hormones or ineffective due to under-dosing. There is no scientific or medical reason to use a custom-compounded treatment that could have an unknown effect on the body when there are numerous FDA-approved options for treating menopausal symptoms, according to the statement.
The statement also examined compounded hormone treatments used to boost testosterone levels in women experiencing sexual dysfunction. There are no FDA-approved testosterone or dehydroepiandrosterone (DHEA) therapies for women, and scientific studies indicate these treatments are not effective in women. There also are concerns about under- or overdosing as well as side effects from these treatments.
Compounded medications also are used to treat thyroid disorders. FDA-approved synthetic thyroid medications to supplement the body’s naturally produced thyroid hormone remain the treatment of choice because they are highly effective and safe, according to the statement. However, some patients may benefit from compounded thyroid medications or desiccated thyroid hormone exacted from animals. Patients prescribed these alternatives need to have their Thyroid-Stimulating Hormone (TSH) levels and symptoms monitored carefully.
New regulations being developed by the FDA may lead to improved safety and quality control for compounded medications, Santoro said. In the meantime, compounded therapies should be used in limited situations due to concerns about the risks of under-dosing, overdosing or contamination.
“Custom-compounded hormones should be reserved for situations in which a patient is allergic to or does not tolerate any of the FDA-approved therapies, and treatment is necessary for his or her health,” Santoro said.
Other authors of the statement include: Glenn D. Braunstein, MD, of Cedars-Sinai Medical Center in Los Angeles, CA; Cherie L. Butts, PhD, of Biogen in Cambridge, MA; Kathryn A. Martin, MD, of Massachusetts General Hospital in Boston, MA; Michael McDermott, MD, University of Colorado School of Medicine in Aurora, CO; and JoAnn V. Pinkerton, MD, of the University of Virginia in Charlottesville, VA.
The statement, “Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement,” was published online in the Society’s Journal of Clinical Endocrinology & Metabolism at http://press.endocrine.org/doi/10.1210/jc.2016-1271. It will be published in the April issue of JCEM.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.